The deal centers around Metabolon's platform for identifying pharmacodynamic, efficacy, and response biomarkers and tracking changes in biological pathways.
The partners will use mass spec to look at markers in Barrett's patients who either progressed to more severe disease states or remained stable over a 10-year period.
The lab will provide researchers in the Asia-Pacific region with access to Quanterix's Simoa technology and biomarker testing, development, and validation services.
In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.
This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.
This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.
